1. This decision relates to an appeal brought by the Appellant p ursuant to section 57 Freedom of Information Act 2000 ("FOIA"). It concerns a request for information made to the 2nd Respondent ("NICE") by the Appellant on 12 January 2025 ("the Request") about two drugs, Ritlecitinib and Baricitinib. This appeal arises from a decision notice ("DN") issued by the 1st Respondent ("the IC") on 11 December 2025 with reference IC-374262-Q2M7 in which the IC agreed that the exemption at section 43(2) FOIA was engaged and the public interest favoured the maintenance of this exemption. 2. For the appeal we had an open bundle of 200 pages and the Appellant and NICE each provided a skeleton. The IC set out his position in an email of 28 September 2026. W hat follows is a summary of the submissions, evidence and our view of the law. It does not seek to provide every step of our reasoning. The absence of a reference to any specific submission or evidence does not mean it has not been considered. In this decision, any page numbers indicated by their inclusion in brackets refer to pages of the bundle. Background 3. NICE is responsible for, amongst other things, assessing the cost and clinical effectiveness of medicines for the NHS. On 12 January 2025 (71) the Request asked NICE: - “Can you please tell me the percentage difference between the cost per monthly prescription between Ritlecitinib (TA958) that was approved on 27 March 2024 and Baricitinib (TA926) that was not approved on 25 October 2023.” "I do not believe this FOI can be considered commercially confidential because I am not asking for the actual costs of each drug, therefore it should not be rejected on those grounds. It has public interest because many people would like to see Baricitinib approved as an alternative option to Ritlecitinib as whilst a similar Jak Inhibitor it will address a different pathway. The public interest is evidence by 10,427 people signing a petition for Baricitinib to be prescribed on the NHS. NICE states the reason for rejecting Baricitinib was based on treatment needing to be continuous (which is the same for the approved Ritlecitinib), that Baricitinib did not show meaningful improvement in quality of life (Ritlecitinib has the same results in hair growth yet approved), and Baricitinib was not cost effective (yet Ritlecitinib must have been to be approved). Hence my question." 4. As at the date of the Request Ritlecitinib was approved by NICE but Baricitinib was not. FOIA 5. FOIA provides that any person making a request for information to a public authority is entitled to be informed in writing if that information is held (section 1(1) (a) FOIA) and if that is the case to be provided with that information (section 1 (1) (b) FOIA). These entitlements are subject to a number of exemptions which can be absolute or subject to the public interest test such as section 43(2) FOIA which provides that "(2) Information is exempt information if its disclosure under this Act would, or would be likely to, prejudice the commercial interests of any person (including the public authority holding it)." 6. Additionally, section 16 FOIA provides that "(1) It shall be the duty of a public authority to provide advice and assistance, so far as it would be reasonable to expect the authority to do so, to persons who propose to make, or have made, requests for information to it" From the Request to Appeal in summary 7. On 29 January 2025 (71) NICE said the information requested was not held. An internal review was requested (70). On 24 February 2025 NICE provided its further response (73) by which it maintained its position and said that it had complied with its section 16 FOIA responsibilities. NICE also referred to its own website and said (74/75): - "Ritlecitinib costs £949.41 per pack of 30 capsules (dictionary of medicines and devices, accessed February 2024)" "The list price of baricitinib is £805.56 for a 28 tablet pack of either 2 mg or 4 mg tablets (excluding VAT, BNF online accessed October 2023)" 8. NICE added "The final guidance also notes however that commercial arrangements are in place for both technologies which provide a discount to the NHS. NICE is unable to provide the post discount pricing of each technology as it is exempt from disclosure under section 43(2) of the FOIA" and indicated that it also relied on section 41 FOIA. 9. On 31 March 2025 the Appellant complained to the IC. This said (132): - "I requested information from NICE on 12 January regarding the percentage cost difference between two drugs, I made it clear I was not asking for actual costs as this would have been rejected on the basis of commercial confidentiality. The response on the 29 January was “Information not held”. I complained on the 9 February based on the fact the information must be held to decide on recommending the use of the drugs, or not. The review upheld the response on the basis that the information is not held in the form requested and the two drugs were not compared. However, the complaint response understood my request and provided the information I was seeking – and therefore proves the information was held and it is my belief NICE did not fulfil its duty to provide advice and assistance from a person seeking advice (section 16 of the FOIA). Therefore, my complaint focuses on the response from NICE to my original request based on the points I made in my complaint email of 9 February – and I would like to know if the ICO think the original response was acceptable. Also whilst the response to my complaint was useful I believe it is wrong in concluding NICE’s response of 29 January was compliant with FOIA legislation and spirit of the legalisation. I would like to know the action taken against NICE in their poor response to the legislation." 10. In the subsequent DN the IC noted that the information was held and gave the decision that: - (a) section 43(2) FOIA was engaged, and the public interest test favoured the maintenance of this exemption (b) section 41 FOIA was not engaged as the information had not been provided by any other person; (c) NICE had not failed to comply with section 16 FOIA; and (d) NICE had failed to comply with sections 1(1)(a), 10(1) and 17(1) FOIA but no further steps were required. 11. The reasons for the appeal were based on 3 headings being (a) commercial confidentiality and public interest (b) no further action and (c) institutional positive bias. The Appellant sought the following outcomes (52): - "For the ICO to: Reconsider if commercial confidentiality applies to my request as the information is in the public domain. Take action against NICE for the breaches that ICO found rather than no further steps which gives an indication these breaches are acceptable. Reflect on positive unconscious bias towards NICE because it is an institution, in grounding their decisions on trust in future behaviour rather than on evidence of past practise. In the decision notice under section "right to appeal" include the name/reference of the form that needs completing appeal. At the moment it currently states "relevant forms" this would considerably help the appellant and not waste the time of all parties. To instruct NICE to issue guidance on the correct approach to FOI requests, that my case is given as an example of bad practise. For my own closure I am writing to confirm that NICE has implemented the guidance." 12. The Appellant's case was also set out in a continuation sheet (28). This raised questions about section 16 FOIA and the IC's decision not to require steps as issues and said: - "While the ICO found a breach of the law for failing to provide the “building blocks,” it nevertheless agreed with NICE that the information was commercially confidential. I do not understand this conclusion, as the information is already public. If NICE considered my request unclear, why did it not seek clarification, or alternatively explain in its response of 29 January that “this may not be exactly what you are seeking, but here are some figures that we have published”? I would have been satisfied with such a response, and it would have avoided both the need for a complaint and the subsequent ICO investigation. However, I would like the tribunal to understand why the ICO felt that applying 43(2) was “credible” when the information was already in the public domain and clearly not confidential. The “Public interest” test becomes immaterial as the information is already published." 13. The Appellant's skeleton also said: - "By taking no action and having no evidence that NICE will improve its practices in the future, NICE can continue to pay disregard to the FOIA. This disregard is not the act of a single officer at NICE or the senior person who would have check the response before issued, but a cultural issue in that NICE’s own guidance is not being followed, let alone meeting the legal requirement. If a public body does not meet FOIA duty, the ICO has the powers to issue an Enforcement Notice under section 52. Though grounds to do so, ICO decided not to." Role of the Tribunal 14. The Tribunal's role in an appeal by section 57 FOIA is set out in section 58 FOIA which provides that: - (1) If on an appeal under section 57 the Tribunal considers— (a) that the notice against which the appeal is brought is not in accordance with the law, or (b) to the extent that the notice involved an exercise of discretion by the Commissioner, that he ought to have exercised his discretion differently, the Tribunal shall allow the appeal or substitute such other notice as could have been served by the Commissioner; and in any other case the Tribunal shall dismiss the appeal. (2) On such an appeal, the Tribunal may review any finding of fact on which the notice in question was based. 15. The Tribunal exercises a full merits appellate jurisdiction and so stands in the shoes of the IC and decides which (if any) exemptions apply. We agree with the Tribunal which said in Peter Wilson -v- The Information Commissioner [2022] UKFTT 0149 that:- "...the Tribunal’s statutory role is to consider whether there is an error of law or inappropriate exercise of discretion in the Decision Notice. The Tribunal may not allow an appeal simply because it disagrees with the Information Commissioner’s Decision. It is also not the Tribunal’s role to conduct a procedural review of the Information Commissioner’s decision making process or to correct the drafting of the Decision Notice.” The Appellant's concerns 16. At the hearing the Appellant confirmed that no further information was being sought by the appeal and the concerns were (in summary) that: - (a) NICE should not have replied saying the information requested was not held and persisted with its justification of that position; (b) the IC should not have agreed with NICE's reliance on section 43 FOIA because the Request made it clear that no confidential information was being sought; (c) the IC was wrong to say that there had been no breach of section 16 FOIA and (d) the IC should have taken some action having agreed that NICE had breached sections 1(1)(a), 10(1) and 17(1) FOIA. Review 17. There seems to us to have been an important lack of a meeting of the minds about what was being requested and then provided. Section 43 FOIA 18. The Request asks for (emphasis added) "the percentage difference between the cost per monthly prescription" and says by way of clarification "I am not asking for the actual costs of each drug." To answer the Request NICE would need to know the intended meaning of the word "cost" and then what that cost was from which the percentage difference could be calculated. As is accepted, notwithstanding the response, that information was held. 19. At the review stage NICE pointed to its own website which said that, in summary, Ritlecitinib costs £949.41 per pack of 30 capsules and the list price of Baricitinib is £805.56. What NICE made clear (seemingly forgetting it was the percentage difference not the costs that had been requested) was that it could not provide the drug prices after the application of any discounts achieved because that level of detail would be likely to prejudice their commercial interests and it was against the public interest to do so. 20. While this was not actually what had been requested it is clear that fortuitously, from that point, the Appellant was content with that answer and was able to calculate the percentage difference of the costs provided. This can be seen, for example (a) in the complaint which said because (emphasis added) " the complaint response understood my request and provided the information I was seeking " (b) in the GRC1 where the Appellant said " NICE subsequently provided the requested information with the drug costs and supplied a link showing the information was already in the public domain " and " The “Public interest” test becomes immaterial as the information is already published ." 21. However, despite the Appellant's satisfaction with the information provided NICE continued to rely on the exemption at section 43(2) FOIA to refuse to disclose the actual discounted costs which had not been requested and was no longer being pursued. 22. From the above we are satisfied that NICE was relying on section 43(2) FOIA to prevent disclosure of the costs actually achieved but this was not the requested information and the cost information actually provided had satisfied the Appellant who had only ever wanted to know the percentage difference between the costs without being told the actual costs or their actual difference in monetary terms. Therefore (a) the exemption at section 43(2) FOIA, relied upon by NICE, was not engaged in respect of the information actually being sought by the Appellant; (b) it is not appropriate for the Tribunal to consider whether section 43(2) FOIA (or any other exemption) might have hypothetically applied to any discounted price information as this was not being sought in the Request or the Appeal; and (c) accordingly, in this regard, the DN was not in accordance with the law. Section 41 FOIA 23. We agreed with the IC that section 41 FOIA did not apply for the same reasons as set out in the DN which has not been appealed or re-asserted by NICE and for the reasons as set out above on section 43 FOIA. Section 16 FOIA 24. A public authority's section 16 FOIA obligations are to provide advice and assistance so far as it would be reasonable to expect from the public authority concerned. 25. In our view the words of the Request (emphasis added) "the percentage difference between the cost per monthly prescription" were open to different interpretations and needed clarification in particular because, even though the Request expressly did not seek the actual cost of each drug, NICE would need to know what the Appellant meant by "cost" to be able to calculate the relevant percentage difference. 26. In hindsight therefore it would have been helpful and appropriate had NICE asked the Appellant to clarify what was meant by cost and whether it was intended to refer to the percentage difference between the published cost or any discounted prices because: - (a) had the Appellant asked for the percentage difference based on the prices in the public domain this could easily have been provided and, based on what happened, would have been; and (b) had the Appellant asked for a percentage difference based on more commercially sensitive information then NICE may have been willing to provide it or may have concluded that this was itself subject to section 43(2) FOIA and offered the less sensitive information. 27. From the above we have concluded that, despite NICE when replying to the Request inviting the Appellant (as requester) to contact NICE if there were any questions, NICE did not fully comply with its section 16 FOIA obligations and accordingly, it is our view that, in this respect, the DN was not in accordance with the law. However in light of Appellant's position on the information that was disclosed no steps are required as a result of this conclusion. Sections 1(1)(a), 10 and 17 FOIA and other matters 28. The complaint says: - "...my complaint focuses on the response from NICE to my original request based on the points I made in my complaint email of 9 February – and I would like to know if the ICO think the original response was acceptable. Also whilst the response to my complaint was useful I believe it is wrong in concluding NICE’s response of 29 January was compliant with FOIA legislation and spirit of the legalisation. I would like to know the action taken against NICE in their poor response to the legislation." 29. As set in the DN, from which there has been no appeal, NICE failed to comply with various FOIA obligations. For balance we note that NICE accepts these points and how it handled the Request more generally and told the Tribunal that lessons had been learnt. 30. The Appellant has asked the Tribunal to require the IC to take action against NICE as a result of those breaches because the " no steps" outcome of the DN "gives an indication these breaches are acceptable." We understand why the Appellant wishes to challenge the IC's decision to take no action against NICE as a result of these issues but we agree with the IC in his Response and email that " The Tribunal does not have jurisdiction in a section 57 FOIA appeal against a DN over whether the Commissioner ought to have issued an enforcement notice against the relevant public authority." While it may well be a matter of frustration for the Appellant, we have no jurisdiction to deal with these points and so have not done so. 31. On the same basis it was not part of our role as set out FOIA to: - (a) carry out a review of how the IC reached conclusions in the DN; (b) decide whether the IC should be required to reflect on his alleged positive unconscious bias; (c) suggest amendments to the standard forms used by the IC; (d) require NICE to issue guidance on the correct approach to FOIA requests; and/or to require NICE to use this case as an example. Decision 32. Accordingly, for the reasons set out above, the DN was in accordance with the law save that NICE did not fully comply with its section 16 FOIA obligations and it was not entitled to rely on section 43(2) FOIA in respect of the information that was actually requested. 33. The appeal is therefore allowed in part and dismissed in part, but no further steps are required. Signed Judge Heald Date: 5 October 2026